

Joint working executive summary

Project title	Transforming pathways around lipid management in primary care in Buckinghamshire
Partner organisation/s	NHS Buckinghamshire CCG Sanofi
Project rationale	<p>This Project has been agreed as part of the Accelerated Access Collaborative (AAC).</p> <p>The AAC was formed in response to the independently chaired Accelerated Access Review published in October 2016. The AAC brings industry, government and the NHS together to remove barriers to uptake of innovations, so that NHS patients have faster access to innovations that can transform care.</p> <p>The AAC supports the rapid uptake of products from 7 high-potential technology areas, selected by leaders in the health and care system, with full evidence-based recommendations from NICE, and have potential to deliver patient benefits and cost-savings in year.</p> <p>PCSK9 inhibitors for the management of hypercholesterolemia were selected as one of the seven NICE recommended rapid uptake products (RUP) to increase patient access and remove barriers across the health innovation landscape.</p> <p>Funding announced by government in July 2017 is available through the new Accelerated Access Collaborative Pathway Transformation Fund (PTF) to help NHS organisations integrate the rapid uptake products into everyday practices. Delivered with the support of the Academic Health Science Networks (AHSNs) the PTF seeks to improve equality of access to these products.</p> <p>The PTF, in relation to PCSK9 inhibitors, combines funding from NHS England, Amgen and Sanofi for selected projects to meet the AAC objectives and increase PCSK9i uptake in appropriately identified patients by addressing barriers such as:</p> <ul style="list-style-type: none"> • Lack of patient identification • Inconsistent Pathways • Limited awareness • Restricted prescribing • Sporadic LDL-C measurement • Treatment complexity <p>19 applications relating to PCSK9 inhibitors from 12 AHSNs were submitted to the AAC for PFT funding (funding from NHS England, Amgen and Sanofi) and 6 were selected, including NHS Buckinghamshire CCG. Please see resources and costs for more detail.</p> <p>NHS England have provided equal PTF to the Academic Health and</p>

	<p>Science Network- North East North Cumbria (AHSN-NENC). AHSN-NENC will distribute this accordingly as agreed by the AAC to the 6 successful sites, one of which being Partner for the Project.</p> <p>The overall cost of this joint working is £109,515 This is made of direct/indirect funding from AHSN-NENC, Amgen, and Sanofi.</p> <p>Buckinghamshire CCG and Sanofi are working in partnership under a joint working agreement to transform lipid management pathways in primary care by</p> <ul style="list-style-type: none"> • Creation of Pharmacist-Led Lipid Management Service • Development of a clear pathway for primary care • Establishing a “Virtual” Consultant-Led Lipid Clinic • Improved Coding <p>After baselining the current quality of data and coding, a strategy to enhance the frequency and accuracy of coding will be put in place. Outcomes data will be captured and used to refine and optimise the service. This will be critical to support the case for sustainability beyond the pilot.</p>
<p>Project period</p>	<p><i>Quarter 3 2020- Quarter 4 2021.</i></p> <p><i>These timelines may slip due to the ongoing Covid 19 crisis.</i></p>
<p>Project objectives</p>	<p>Predicted benefit to patients:</p> <ul style="list-style-type: none"> • Patients might expect more equitable and consistent care as well as improved and quicker access to care, better education around FH, better access to treatment options, improvement in clinical markers such as lipid levels, a clearer pathway of care with care being delivered closer to home and a better experience of the system. <p>Predicted benefit to CCG:</p> <ul style="list-style-type: none"> • Decrease in numbers of patients reviewed with suboptimal lipid control in Bucks • Increases in numbers of patients with changes to statin therapy, prescribed adjunctive ezetimibe • Appropriate Patients referred, assessed and potentially initiated on PCSK9i • Reduce numbers of patients at risk of secondary CVD <p>Predicted benefit to Sanofi:</p> <ul style="list-style-type: none"> • The project aims to increase the hypercholesterolaemia and mixed dyslipidaemia diagnosis rates. Patients diagnosed with these conditions will be treated with cholesterol lowering medicines which may include Sanofi medicines for suitable patients in line with NICE TA393 and or local / national guidelines. • Greater customer understanding • Improved reputation through partnering with the AAC initiative <p><i>The results of the project will be written up and published to enable the learnings from the project to be shared.</i></p>

Contact details	<p><i>Sanofi- Fleur Chandler, Director of Market Access</i> <i>410 Thames Valley Park Drive,</i> <i>Reading,</i> <i>Berkshire.</i> <i>RG6 1PT.</i> <u>Gb-marketaccess@sanofi.com</u> <i>Telephone-0845-023-04441</i></p> <p>Dr Raj Thakkar, Planned Care Clinical Director, Buckinghamshire CCG and LTC and CVD Clinical Lead, Thames Valley Strategic Clinic Buckinghamshire CCG Second Floor, The Gateway, Gatehouse Road, Aylesbury, Buckinghamshire, HP19 8FF <i>01296 587220</i></p>
------------------------	---